drugset / Trial / NCT05739851
Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fasting State
RandomizedCrossoverOpen-labelTreatment
Summary
This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229\_01(2.5/500 mg) at fasting state.
Timeline
- Start
- 2023-03-18
- Primary completion
- 2023-04-14
- Completion
- 2023-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DA-1229_01 | Unknown | — | Oral |
Indications
No indication recorded.